215 related articles for article (PubMed ID: 31272940)
1. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle.
Ghandour R; Ashbrook C; Freifeld Y; Singla N; El-Asmar JM; Lotan Y; Margulis V; Eggener S; Woldu S; Bagrodia A
Eur Urol Oncol; 2020 Apr; 3(2):198-206. PubMed ID: 31272940
[TBL] [Abstract][Full Text] [Related]
2. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
Woldu SL; Moore JA; Ci B; Freifeld Y; Clinton TN; Aydin AM; Singla N; Laura-Maria K; Hutchinson RC; Amatruda JF; Sagalowsky A; Lotan Y; Arriaga Y; Margulis V; Xie Y; Bagrodia A
Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
[TBL] [Abstract][Full Text] [Related]
3. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
4. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
5. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
6. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
7. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
[TBL] [Abstract][Full Text] [Related]
8. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
[TBL] [Abstract][Full Text] [Related]
9. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
10. Bilateral laparoscopic postchemotherapy retroperitoneal lymph-node dissection in nonseminomatous germ cell tumors--a comparison to template dissection.
Aufderklamm S; Todenhöfer T; Hennenlotter J; Gakis G; Mischinger J; Mundhenk J; Germann M; Stenzl A; Schwentner C
J Endourol; 2013 Jul; 27(7):856-61. PubMed ID: 23516988
[TBL] [Abstract][Full Text] [Related]
11. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
13. Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database.
Weiner AB; Pearce SM; Eggener SE
Cancer; 2017 Jan; 123(2):245-252. PubMed ID: 27626903
[TBL] [Abstract][Full Text] [Related]
14. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of post-chemotherapy retroperitoneal lymph node dissection in metastatic nonseminomatous germ cell tumour: A systematic review.
Haarsma R; Blok JM; van Putten K; Meijer RP
Eur J Surg Oncol; 2020 Jun; 46(6):999-1005. PubMed ID: 32173176
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.
Hamilton RJ; Nayan M; Anson-Cartwright L; Atenafu EG; Bedard PL; Hansen A; Chung P; Warde P; Sweet J; O'Malley M; Sturgeon J; Jewett MAS
J Clin Oncol; 2019 Aug; 37(22):1919-1926. PubMed ID: 30802156
[TBL] [Abstract][Full Text] [Related]
17. Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998-2011).
Hugen CM; Hu B; Jeldres C; Burton C; Nichols CR; Porter CR; Daneshmand S
Urol Oncol; 2016 Nov; 34(11):487.e7-487.e11. PubMed ID: 27372281
[TBL] [Abstract][Full Text] [Related]
18. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
[TBL] [Abstract][Full Text] [Related]
19. Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours.
Gerdtsson A; Negaard HFS; Almås B; Bergdahl AG; Cohn-Cedermark G; Glimelius I; Halvorsen D; Haugnes HS; Hedlund A; Hellström M; Holmberg G; Karlsdóttir Á; Kjellman A; Larsen SM; Thor A; Wahlqvist R; Ståhl O; Tandstad T
BJU Int; 2024 Jun; 133(6):717-724. PubMed ID: 38293778
[TBL] [Abstract][Full Text] [Related]
20. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.
Carver BS; Serio AM; Bajorin D; Motzer RJ; Stasi J; Bosl GJ; Vickers AJ; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5603-8. PubMed ID: 17998544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
